TipHub

₹3.03

▲ +0.08 +2.71%

29 Jul 2026

BSE Listed

GSM · GSM 0
What does GSM · GSM 0 mean?
BSE · Graded Surveillance Measure (GSM 0)GSM targets fundamentally weak companies whose price doesn't square with their financials (tiny net worth or negative/extreme P/E). Practical meaning: the exchange doubts the price is backed by the business. Stage 0 is a watchlist; each higher stage makes the stock progressively harder to trade — tighter bands, full upfront margin, weekly-only trading, and at Stage IV no upward price movement at all. Exiting requires a quarterly review finding the criteria no longer met.Criteria: Shortlisted on objective financial parameters — net worth, net fixed assets, price-to-earnings multiple and market capitalisation. Stage 0 = base surveillance watchlist (identified under GSM, no graded price restriction yet); Stages I–VI add escalating curbs (price band, 100% margin, periodic call auction, settlement on a gross/trade-for-trade basis, no upward price movement).

Transgene Biotek Ltd. (526139)

Volume: 9,157Avg Vol 1W: 16,721Avg Vol 1M: 26,60652W Range:₹1.83₹5.17
BSE www.transgenebiotek.com AI Report
Key Ratios
Checked just now
Market Cap₹23 Cr
Current Price₹3.03
Previous Close₹2.95
High / Low (52w)₹5.17 / ₹1.83
Volume9,157
Avg Vol (1W)16,721
Avg Vol (1M)26,606
Stock P/E—
Book Value₹1.11
Dividend Yield0%
ROE-19.73%
ROA-114.85%
Revenue (TTM)—
Revenue Growth—
Profit Margin-825%
Total Debt—
Shares Outstanding8 Cr
Face Value—
EPS (TTM)₹0
P/B2.74
Debt / Equity1.38
50 DMA₹3.05
200 DMA₹3
Day change+2.71%
SurveillanceGSM · GSM 0
Price Chart
₹3.03▼ 35.26% · 1Y
₹5₹24.8L
2025-07-29
2026-07-29

20-day avg volume: 27K shares

Pros
  • Company is almost debt-free.
Cons
  • Company is loss-making at the latest annual result.
Quarterly Results
MetricJun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026
Revenue₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
EBITDA₹0 Cr₹0 Cr₹0 Cr₹-1 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Net Profit₹0 Cr₹0 Cr₹0 Cr₹-1 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
EPS————————
Profit & Loss (Annual)
MetricSept 2024Dec 2024Mar 2025Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026
Revenue₹0 Cr₹0 Cr₹1 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
EBITDA₹0 Cr₹0 Cr₹0 Cr₹-1 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Net Profit₹0 Cr₹0 Cr₹-1 Cr₹-1 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
EPS——-0.09—————
Balance Sheet
MetricMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Total Assets₹187 Cr₹177 Cr₹167 Cr₹157 Cr₹147 Cr₹142 Cr₹142 Cr₹144 Cr
Total Liabilities₹134 Cr₹133 Cr₹134 Cr₹135 Cr₹130 Cr₹131 Cr₹132 Cr₹134 Cr
Equity₹52 Cr₹44 Cr₹33 Cr₹22 Cr₹17 Cr₹11 Cr₹11 Cr₹10 Cr
Total Debt————————
Cash Flow
MetricMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Operating₹-1 Cr₹-2 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹1 Cr
Investing₹3 Cr₹2 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹-2 Cr
Financing₹-2 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹1 Cr
Free Cash Flow₹-1 Cr₹-2 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Shareholding
Promoter 23.64% Institutions 0% Public 76.36%
Efficiency & Working Capital
ROCE-2.3%
Interest Coverage-1.8
Dividend Payout—
Debtor Days12 d
Inventory Days48 d
Payable Days2231 d
Cash Conversion Cycle-2172 d
Working Capital Days59 d
Shareholding Details

As of 2026-06-30

Promoter23.6%
FII0%
DII0%
Institutions0%
Public76.4%
Promoter Pledge0%
No. of Shareholders13,817
Shareholding Pattern

Quarterly — figures in %. Latest 12 quarters.

PeriodSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Promoters23.6%23.6%23.6%23.6%23.6%23.6%23.6%23.6%23.6%23.6%23.6%23.6%
FIIs0%0%0%0%0%0%0%0%0%0%0%0%
DIIs0%0%0%0%0%0%0%0%0%0%0%0%
Public76.4%76.4%76.4%76.4%76.4%76.4%76.4%76.4%76.4%76.4%76.4%76.4%
Promoter Pledge0%0%0%0%0%0%0%0%0%0%0%0%
No. of Shareholders11,36012,22012,42612,76612,96313,30713,58313,47513,46113,54513,76713,817
Returns History (ROE / ROCE / ROA)
PeriodROEROCEROAP/E
202503————
Major Shareholders (>1%)
NameCategoryStakeShares
Dr K Koteswara RaoShareholding of Promoter and Promoter Group21.9%1.52 Cr
Kollipara NirmalaShareholding of Promoter and Promoter Group1.7%11,92,000
Kollipara SrinivasShareholding of Promoter and Promoter Group0%24,000
Board of Directors
NameDesignationYear
K Koteswara RaoChairman & Managing Director2025
Sujana KadiamIndependent Non Exe. Director2025
Swetha MarriIndependent Non Exe. Director2025
Santosh KumarIndependent Non Exe. Director2025
Ankita JainCompany Secretary2025
Segments — Product
SegmentRevenueShare
Diagnostic Services₹0 Cr24.6%
CRO Services₹0 Cr75.4%
Capital Structure (₹ Cr)
YearFace ValueAuthorisedIssuedPaid-up
2025₹10767676
Corporate Actions
TypeDateValueRemark
forthcoming2026-08-07Board Meetings—
Related-Party Transactions (₹ Cr)
YearSubsidiariesAssociatesJVKMPOthersTotal
2025000101
2025000101
2025000000
Company Information
Incorporated1990
ChairmanK Koteswara Rao
AuditorVasavi & Co
Investor Email[email protected]
🌐 www.transgenebiotek.com ↗

📍 Plot No 69 & 70 IDA Bollaram, Sangareddy, Telangana, 502325

Technical AnalysisPremium

Technical analysis (Premium)

Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.

Log inSign up free

More stocks

Uniroyal Marine Exports LimitedManor Estates & Industries Ltd.Shervani Industrial Syndicate Ltd.BN AgrochemSupertex Industries Ltd.Shetron Ltd.MPL Plastics Ltd.Nikhil Adhesives Ltd.Spenta International Ltd.Multibase India Ltd.Andrew Yule & Company Ltd.Ludlow Jute & Specialities Ltd.All “52” stocks →

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search